Related Experiment Videos
Bcl-2 oncoprotein expression in acute myeloid leukemia
1Dipartimento di Science Mediche, Oncologiche e Radiologiche, Università di Modena, Italy.
Haematologica
|March 1, 1995
Summary
The anti-apoptotic oncoprotein Bcl-2 is highly expressed in acute myeloid leukemia (AML) blasts, particularly during relapse. This suggests potential therapeutic strategies targeting Bcl-2 in AML treatment.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Bcl-2, a mitochondrial oncoprotein inhibiting apoptosis, is well-documented in lymphoproliferative diseases.
- Limited research exists on Bcl-2 expression in myeloproliferative conditions like AML.
Purpose of the Study:
- To investigate Bcl-2 expression in acute myeloid leukemia (AML).
- To explore correlations between Bcl-2 expression and AML subtypes, patient demographics, and clinical parameters.
Main Methods:
- Immunocytochemical analysis of 63 AML cases at onset and 10 relapses.
- Assessment of Bcl-2 protein presence and percentage in leukemic blasts.
Main Results:
- Bcl-2 was expressed in 87.3% of AML cases at onset and 100% of relapses.
- Higher percentages of Bcl-2 positive blasts were observed in relapses compared to onset.
- No statistical correlation was found between Bcl-2 expression and FAB subtypes, sex, age, or white blood cell count.
Conclusions:
- The majority of AML blasts express Bcl-2, contributing to leukemic cell survival by blocking apoptosis.
- In vitro studies are recommended to understand the impact of chemotherapies and modulatory substances on Bcl-2 in AML.